Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | President and COO | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,088 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,714 · Balance 185,088 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 25,714 | $188.88 | $4,856,963.18 |
DisclosureSEC source: 0001214659-26-012547 · marketforms-74095.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,088 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,046 | $139.07 | $562,661.04 |
DisclosureSEC source: 0001214659-26-010831 · marketforms-73877.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,802 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 23,355 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · derivative · entry 9 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,355 shares Expires 2030-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F9 · derivative.exercise_date: The option was 100% exercisable on December 19, 2022. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,000 | $122.58 | $245,162.00 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 8 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,678 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F8 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $122.00 to $122.815 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,296 | $121.01 | $761,860.07 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 7 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,678 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F7 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.585 to $121.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 12,917 | $119.86 | $1,548,205.79 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 6 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,974 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F6 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $119.515 to $120.2 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,500 | $119.04 | $535,680.00 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 5 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,891 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F5 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $118.505 to $119.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,868 | $117.70 | $1,043,737.00 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,391 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F4 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $117.37to $118.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 10,420 | $116.82 | $1,217,266.48 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,259 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F3 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $116.37 to $117.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 33,354 | $115.90 | $3,865,695.25 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,679 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. F2 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $115.35 to $116.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 23,355 | $67.85 | $1,584,636.75 |
DisclosureSEC source: 0001214659-26-010645 · marketforms-73808.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,888 | $85.32 | $246,407.63 |
DisclosureSEC source: 0001214659-26-009657 · marketforms-73657.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,678 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,238 | $93.89 | $210,132.53 |
DisclosureSEC source: 0001214659-26-009065 · marketforms-73631.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,566 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,160 | $53.26 | $221,549.12 |
DisclosureSEC source: 0001214659-26-006710 · marketforms-73241.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,804 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,844 | $57.15 | $162,531.19 |
DisclosureSEC source: 0001214659-26-005674 · marketforms-73054.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,964 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,321 | $60.76 | $141,026.28 |
DisclosureSEC source: 0001214659-26-005124 · marketforms-72991.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,808 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,294 | $46.71 | $200,571.88 |
DisclosureSEC source: 0001214659-26-002445 · marketforms-72308.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,129 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 18,205 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · derivative · entry 8 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,205 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F7 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 32,300 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,300 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F6 · derivative.exercise_date: The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,541 | $53.11 | $188,062.51 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · nonDerivative · entry 6 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,788 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F5 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $53.01 to $53.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 26,952 | $52.69 | $1,419,993.07 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · nonDerivative · entry 5 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,329 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F4 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $52.00 to $52.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 16,616 | $51.42 | $854,444.57 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,281 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F3 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $51.00 to $51.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 21,858 | $50.32 | $1,099,916.42 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,897 F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F2 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 32,300 | $26.66 | $861,118.00 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 18,205 | $23.33 | $424,722.65 |
DisclosureSEC source: 0001214659-26-002179 · marketforms-72245.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · derivative · entry 10 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,052 Underlying: Common Stock · 500 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F4 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 712 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · derivative · entry 9 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,300 Underlying: Common Stock · 712 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F3 · derivative.exercise_date: The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,750 | $50.04 | $87,571.75 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · nonDerivative · entry 6 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,250 F2 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 712 | $26.66 | $18,981.92 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · nonDerivative · entry 5 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 500 | $23.33 | $11,665.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · derivative · entry 8 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,705 Underlying: Common Stock · 1,000 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F4 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,012 Underlying: Common Stock · 1,500 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F3 · derivative.exercise_date: The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,500 | $50.23 | $175,787.50 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,788 F2 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,500 | $26.66 | $39,990.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,000 | $23.33 | $23,330.00 |
DisclosureSEC source: 0001214659-26-002041 · marketforms-72141.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,705 | $46.58 | $125,988.08 |
DisclosureSEC source: 0001214659-26-001237 · marketforms-72015.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,788 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,390 | $44.91 | $107,330.12 |
DisclosureSEC source: 0001214659-26-000873 · marketforms-71940.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,493 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionStock Option (right to buy) · Derivative | 3,279 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-000508 · marketforms-71848.xml · derivative · entry 3 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,279 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vested on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 23,279 | $40.00 | $931,160.00 |
DisclosureSEC source: 0001214659-26-000508 · marketforms-71848.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,883 F1 · shares: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 3,279 | $8.82 | $28,920.78 |
DisclosureSEC source: 0001214659-26-000508 · marketforms-71848.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,776 | $26.50 | $47,070.22 |
DisclosureSEC source: 0001214659-25-017221 · marketforms-71343.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,883 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 68,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017000 · marketforms-71304.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,659 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,755 | $32.08 | $88,378.75 |
DisclosureSEC source: 0001214659-25-015973 · marketforms-71201.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,919 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 17,606 | $31.44 | $553,608.35 |
DisclosureSEC source: 0001214659-25-015766 · marketforms-71184.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,674 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 79,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-015587 · marketforms-71166.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,280 F1 · shares: Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,240 | $30.88 | $69,160.00 |
DisclosureSEC source: 0001214659-25-015366 · marketforms-71135.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,495 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 23,747 | $32.19 | $764,344.69 |
DisclosureSEC source: 0001214659-25-014773 · marketforms-70957.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,735 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 206 | $29.16 | $6,007.17 |
DisclosureSEC source: 0001214659-25-014664 · marketforms-70939.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,482 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: The balance has been adjusted to reduce the number of shares beneficially owned to correct an administrative error. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,840 | $25.96 | $47,773.76 |
DisclosureSEC source: 0001214659-25-012705 · marketforms-70338.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,529 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,189 | $28.36 | $90,452.80 |
DisclosureSEC source: 0001214659-25-011607 · marketforms-70150.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,153 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.